KV Pharmaceutical News
Most Popular KV Pharmaceutical Story
Columbia shares plunge after FDA staffers blast birth gel app
Regulators at the FDA issued a brutal review for Columbia Laboratories' ($CBRX) application for its progesterone vaginal gel to prevent preterm delivery, saying the developer didn't provide the data Read more...
Latest Headlines
- January 18, 2012
- July 14, 2010
- June 14, 2010
- February 9, 2009
- January 27, 2009
- August 10, 2007
- July 30, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
